Smith+Nephew to showcase leading, innovative AI-driven robotic-assisted solutions for personalized orthopaedic surgery at AAOS 2024 Annual Meeting
12 Febbraio 2024 - 9:00PM
UK Regulatory
Smith+Nephew to showcase leading, innovative AI-driven
robotic-assisted solutions for personalized orthopaedic surgery at
AAOS 2024 Annual Meeting
Smith+Nephew (LSE: SN, NYSE:SNN), the global medical technology
company, announces it will provide a glimpse into the future at
AAOS 2024. With a first opportunity to see a forthcoming new
feature* for its CORI◊ Surgical System, this exclusive
image-agnostic* robotic-assisted surgical solution is designed to
further help personalize surgery, advance efficiencies, and
optimize performance across Smith+Nephew’s orthopaedic
reconstruction portfolio.
The power of one robotic-assisted platform
Smith+Nephew’s CORI Surgical System – a next-generation handheld
robotic platform - supports the entire continuum of care in knee
arthroplasty (unicompartmental, total, revision) and a
comprehensive solution for navigated total hip arthroplasty (THA).
Robotic-assisted surgery has been shown to help improve surgical
outcomes and cost effectiveness compared to conventional
techniques.1-3
- The CORI Surgical System is the only robotic-assisted solution
indicated for revision total knee arthroplasty, and RI.KNEE
software enables joint line restoration4 and improves
patient reported outcomes (pain and PROMIS
Depression).4
- The CORI Digital Tensioner provides objective gap data and
quantifies joint laxity prior to making bone
resections6-8 in total knee arthroplasty (TKA) resulting
in more consistent, repeatable joint balancing and alignment
compared to manual tensioning.8
- Use of a navigated surgery, such as RI.HIP NAVIGATION, enables
a computer-guided approach that demonstrates significantly lower
revision rates, lower risk of revision, and higher patient
satisfaction when compared with traditional THA.9
- The CORI Surgical System has the smallest
footprint11 and offers more indications and specialized
tools than competitive solutions to help accommodate the high
growth of outpatient/ASC hip and knee procedures in the US.
Personalizing surgery
Delivering solutions for differing patient types coupled with
planning and execution tools is essential to personalizing surgery.
By individualizing the episode of care, patients have shown better
outcomes such as early recovery and early functional outcomes
compared to conventional UKA surgery.12-15
RI.KNEE ROBOTICS v2.0 – Personalized Planning software powered
by AI - provides AI-powered reference values as guidance for
planning and enables surgeons to set preferences for initial
implant starting positions that are customized to patient
deformity.
“Smith+Nephew’s technology platform is the only one in the
market that allows for personalized planning using simulation and
AI. The RI.HIP Modeler allows for impingement analysis based
on an individual patient profile, while RI.KNEE software utilizes
AI for personalized planning and implant placement. When
introducing personalized options to manage specific pathologies, we
see increased patient satisfaction and clinical
outcomes. These continue to elevate the level of care we as
surgeons may provide to our patients,” said Thorsten Seyler, MD
PhD, Associate Professor of Orthopedics at Duke University.
Smith+Nephew's CORI Surgical System and RI.KNEE
Robotics v2.0
Proven economic benefits
Smith+Nephew’s robotic-assisted procedural solutions have
positive effects on the healthcare economic landscape. For example,
patients who received Smith+Nephew robotic-assisted UKA could be
discharged in less than 24 hours without complications or
readmissions.14
To learn more about how these advancements in robotic-assisted
and personalized surgery support ‘Precision in Motion’ - the
company’s uncompromising commitment to freedom of movement - please
visit the Smith+Nephew booth (#5469) at the American Academy of
Orthopaedic Surgeons 2024 Annual Meeting from February 12-16 in San
Francisco, CA.
- ends –
Enquiries
Media
David Snyder
+1 978-749-1440
Smith+Nephew
References
- Chen K et al. Cost-effectiveness analysis of robotic
arthroplasty. Lonner JH, editor. Robotics in Knee and Hip
Arthroplasty: Springer; 2019
- Yeroushalmi D, Feng J, Nherera L, Trueman P, Schwarzkopf R.
Early economic analysis of robotic-assisted unicondylar knee
arthroplasty may be cost effective in patients with end-stage
osteoarthritis. J Knee Surg. 2020; DOI:
10.1055/s-0040-1712088.
- Nherera LM, Verma S, Trueman P, Jennings S. Early economic
evaluation demonstrates that noncomputerized tomography
robotic-assisted surgery is cost-effective in patients undergoing
unicompartmental knee arthroplasty at high-volume orthopaedic
centres. Adv Orthop. 2020;3460675OK with changes to RI.HIP
Navigation statement
- Seyler MT. Revision total knee arthroplasty with a imageless,
2nd generation robot system. Podium Presentation at: 2023 Members
Meeting of The Knee Society; September 7–9, 2023; Monterey,
California, US.
- Smith+Nephew 2022. Optimus TKA Tensioner Gap Assessment
Verification Report. Internal Report. 10059269.
- Smith+Nephew 2021. Tensioner Design Verification Test Report.
Internal Report. TR100123.
- Smith+Nephew 2022. Tensioner KPC: Tensioner Calibration Check.
Internal Report. TR100116, Rev.B.
- Smith+Nephew 2022. Tensioner whitepaper supporting evidence
report. 10073166 REV A.
- Davis ET, McKinney KD, Kamali A, Kuljaca S, Pagkalos J. Reduced
Risk of Revision with Computer-Guided Versus Non-Computer-Guided
THA: An Analysis of Manufacturer-Specific Data from the National
Joint Registry of England, Wales, Northern Ireland and the Isle of
Man. JB JS Open Access. 2021 Jul 28;6(3):e21.00006. doi:
10.2106/JBJS.OA.21.00006. PMID: 34337286; PMCID: PMC8318654.
- Ulivi M, Orlandini L, Pascale W, Consonni O, Sansone V.
Intraoperative validation of navigated limb measurements in THA
using a pinless femoral array. J Arthroplasty.
2014;29(5):1026-102)
- Smith+Nephew 2020. Comparison of operating room footprint for
robotic-assisted knee arthroplasty systems. Internal Report.
EO.REC.PCS015.002.v1.
- Canetti R, Batailler C, Bankhead C, Neyret P, Servien E, Lustig
S. Faster return to sport after robotic-assisted lateral
unicompartmental knee arthroplasty: a comparative study. Arch
Orthop Trauma Surg. 2018;138:1765-1771.
- Mergenthaler G, Batailler C, Lording T, Servien E, Lustig S. Is
robotic-assisted unicompartmental knee arthroplasty a safe
procedure? A case control study. Knee Surg Sports Traumatol
Arthrosc. 2020; doi: 10.1007/s00167-020-06051-z.
- Sephton BM, Shearman A, Nathwani D. 24 hour discharge in
unicompartmental knee replacement using the NAVIO◊
robotic system: A retrospective analysis. Poster presented at:
European Knee Society Arthroplasty Conference;2-3 May, 2019;
Valencia, Spain
- Shearman AD, Sephton BM, Wilson J, Nathwani DK. Arch Orthop
Trauma Surg. 2021; 2021;141:2147– 2153
* Pending 510(k) clearance
About Smith+Nephew
Smith+Nephew is a portfolio medical technology company focused on
the repair, regeneration and replacement of soft and hard tissue.
We exist to restore people’s bodies and their self-belief by using
technology to take the limits off living. We call this purpose
‘Life Unlimited’. Our 19,000 employees deliver this mission every
day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
business units of Orthopaedics, Sports Medicine & ENT and
Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of Covid, such as the depth and longevity of
its impact, government actions and other restrictive measures taken
in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
Covid; economic and financial conditions in the markets we serve,
especially those affecting healthcare providers, payers and
customers (including, without limitation, as a result of Covid);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal and financial compliance
risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our
suppliers (including, without limitation, as a result of Covid);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments;
relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to
natural disasters, weather and climate change related events;
changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC’s website at www.
sec.gov, for a discussion of certain of these factors. Any
forward-
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Mag 2023 a Mag 2024